The relationship between familial-genetic risk and pharmacological treatment in a Swedish national sample of patients with major depression, bipolar disorder, and schizophrenia.
Journal
Molecular psychiatry
ISSN: 1476-5578
Titre abrégé: Mol Psychiatry
Pays: England
ID NLM: 9607835
Informations de publication
Date de publication:
20 Dec 2023
20 Dec 2023
Historique:
received:
24
06
2023
accepted:
01
12
2023
revised:
28
11
2023
medline:
21
12
2023
pubmed:
21
12
2023
entrez:
20
12
2023
Statut:
aheadofprint
Résumé
Using Swedish registers, we examine whether the prescription of and the response to antidepressants (AD), mood stabilizers (MS), and antipsychotics (AP) in the treatment of, respectively, major depression (MD), bipolar disorder (BD), and schizophrenia (SZ), are influenced by familial-genetic risk. We examined individuals born in Sweden 1960-1995 with a first diagnosis of MD (n = 257,177), BD (n = 23,032), and SZ (n = 4248) from 2006 to 2018. Drug classes and Defined Daily Dose (DDD) were obtained from the Pharmacy register using the Anatomical Therapeutic Chemical system. We utilized the Familial Genetic Risk Scores (FGRS) calculated from morbidity risks in first- through fifth degree relatives. Treatment with antidepressants (AD) in MD, mood-stabilizers (MS) in BD, and antipsychotics (AP) in SZ were associated with significantly higher disorder-specific familial-genetic risks. Using dosage trajectory analysis of AD, MS, and AP treatment for MD, BD, and SZ, respectively, familial-genetic risk was positively associated with higher and/or increasing drug dosages over time. For MD and BD, examining cases started on the most common pharmacologic treatment class (SSRIs for MD and "other anti-epileptics" for BD), familial-genetic risks were significantly lower in those who did not versus did later receive treatment from other AD and MS classes, respectively. Higher familial-genetic risk for BD predicted switching AD medication in cases of MD. Among pharmacologically treated cases of BD, familial-genetic risk was significantly higher for those treated with lithium. In a large population-based patient cohort, we found evidence of a wide-spread association between higher familial-genetic risk and i) increased likelihood of receiving pharmacologic treatment but 2) responding more poorly to it-as indicated by a switching of medications -- and/or requiring higher doses. Further investigations into the clinical utility of genetic risk scores in the clinical managements of MD, BD, and SZ are warranted.
Identifiants
pubmed: 38123723
doi: 10.1038/s41380-023-02365-9
pii: 10.1038/s41380-023-02365-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 2002;63:942–7.
pubmed: 12416605
doi: 10.4088/JCP.v63n1013
Uher R. Genes, environment, and individual differences in responding to treatment for depression. Harv Rev Psychiatry. 2011;19:109–24.
pubmed: 21631158
doi: 10.3109/10673229.2011.586551
Franchini L, Serretti A, Gasperini M, Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res. 1998;32:255–9.
pubmed: 9789202
doi: 10.1016/S0022-3956(98)00004-1
Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry. 2004;161:780–96.
pubmed: 15121641
doi: 10.1176/appi.ajp.161.5.780
Johnson D, Wilke MA, Lyle SM, Kowalec K, Jorgensen A, Wright GE, et al. A systematic review and analysis of the use of polygenic scores in pharmacogenomics. Clin Pharmacol Ther. 2022;111:919–30.
pubmed: 34953075
doi: 10.1002/cpt.2520
Meerman JJ, Ter Hark SE, Janzing JG, Coenen MJ. The potential of polygenic risk scores to predict antidepressant treatment response in major depression: a systematic review. J Affect Disord. 2022;304:1–11.
pubmed: 35151671
doi: 10.1016/j.jad.2022.02.015
Fabbri C, Serretti A. Genetics of treatment outcomes in major depressive disorder: present and future. Clin Psychopharmacol Neurosci. 2020;18:1–9.
pubmed: 31958900
pmcid: 7006978
doi: 10.9758/cpn.2020.18.1.1
Pain O, Hodgson K, Trubetskoy V, Ripke S, Marshe VS, Adams MJ, et al. Identifying the common genetic basis of antidepressant response. Biol Psychiatry Glob Open Sci. 2022;2:115–26.
pubmed: 35712048
doi: 10.1016/j.bpsgos.2021.07.008
Nøhr AK, Forsingdal A, Moltke I, Howes OD, Vitezic M, Albrechtsen A, et al. Polygenic heterogeneity in antidepressant treatment and placebo response. Transl Psychiatry. 2022;12:456.
pubmed: 36309483
pmcid: 9617908
doi: 10.1038/s41398-022-02221-4
Wimberley T, Gasse C, Meier SM, Agerbo E, MacCabe JH, Horsdal HT. Polygenic risk score for schizophrenia and treatment-resistant schizophrenia. Schizophr Bull. 2017;43:1064–9.
pubmed: 28184875
pmcid: 5581885
doi: 10.1093/schbul/sbx007
Werner MCF, Wirgenes KV, Haram M, Bettella F, Lunding SH, Rødevand L, et al. Indicated association between polygenic risk score and treatment-resistance in a naturalistic sample of patients with schizophrenia spectrum disorders. Schizophr Res. 2020;218:55–62.
pubmed: 32171635
doi: 10.1016/j.schres.2020.03.006
Kowalec K, Lu Y, Sariaslan A, Song J, Ploner A, Dalman C, et al. Increased schizophrenia family history burden and reduced premorbid IQ in treatment-resistant schizophrenia: a Swedish National Register and Genomic Study. Mol Psychiatry. 2021;26:4487–95.
pubmed: 31712719
doi: 10.1038/s41380-019-0575-1
Zhang J-P, Robinson D, Yu J, Gallego J, Fleischhacker WW, Kahn RS, et al. Schizophrenia polygenic risk score as a predictor of antipsychotic efficacy in first-episode psychosis. Am J Psychiatry. 2019;176:21–8.
pubmed: 30392411
doi: 10.1176/appi.ajp.2018.17121363
Gasse C, Wimberley T, Wang Y, Mors O, Børglum A, Als TD, et al. Schizophrenia polygenic risk scores, urbanicity and treatment-resistant schizophrenia. Schizophr Res. 2019;212:79–85.
pubmed: 31447354
doi: 10.1016/j.schres.2019.08.008
Fusar-Poli L, Rutten BP, van Os J, Aguglia E, Guloksuz S. Polygenic risk scores for predicting outcomes and treatment response in psychiatry: hope or hype? Int Rev Psychiatry. 2022;34:663–75.
Kendler KS, Ohlsson H, Sundquist J, Sundquist K. Family genetic risk scores and the genetic architecture of major affective and psychotic disorders in a Swedish national sample. JAMA Psychiatry. 2021;78:735–43.
pubmed: 33881469
doi: 10.1001/jamapsychiatry.2021.0336
Kendler KS, Ohlsson H, Sundquist J, Sundquist K. The patterns of family genetic risk scores for eleven major psychiatric and substance use disorders in a Swedish national sample. Transl Psychiatry. 2021;11:1–8.
doi: 10.1038/s41398-021-01454-z
Kendler K, Ohlsson H, Sundquist J, Sundquist K. The impact of sex, age at onset, recurrence, mode of ascertainment and medical complications on the family genetic risk score profiles for alcohol use disorder. Psychol Med. 2023;53:1732–40.
pubmed: 34620257
doi: 10.1017/S0033291721003317
Kendler KS, Ohlsson H, Mościcki EK, Sundquist J, Edwards AC, Sundquist K. Genetic liability to suicide attempt, suicide death and psychiatric and substance use disorders on the risk for suicide attempt and suicide death: a Swedish national study. Psychol Med. 2023;53:1639–48.
pubmed: 37010214
doi: 10.1017/S0033291721003354
Kendler KS, Ohlsson H, Bacanu S, Sundquist J, Sundquist K. Differences in genetic risk score profiles for drug use disorder, major depression and ADHD as a function of sex, age at onset, recurrence, mode of ascertainment and treatment. Psychol Med. 2023;53:3448–60.
pubmed: 35098912
doi: 10.1017/S0033291721005535
Kendler KS, Ohlsson H, Sundquist J, Sundquist K. The moderation of the genetic risk for alcohol and drug use disorders in a swedish national sample by the genetic aptitude for educational attainment. Psychol Med. 2023;53:3077–84.
pubmed: 37449484
doi: 10.1017/S0033291721005134
Kendler KS, Rosmalen JGM, Ohlsson H, Sundquist J, Sundquist K. A distinctive profile of family genetic risk scores in a Swedish national sample of cases of fibromyalgia, irritable bowel syndrome, and chronic fatigue syndrome compared to rheumatoid arthritis and major depression. Psychol Med. 2023;53:3879–86.
pubmed: 35354508
doi: 10.1017/S0033291722000526
Fanelli G, Benedetti F, Kasper S, Zohar J, Souery D, Montgomery S, et al. Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2021;108:110170.
doi: 10.1016/j.pnpbp.2020.110170
Amare AT, Schubert KO, Hou L, Clark SR, Papiol S, Heilbronner U, et al. Association of polygenic score for schizophrenia and HLA antigen and inflammation genes with response to lithium in bipolar affective disorder: a genome-wide association study. JAMA Psychiatry. 2018;75:65–74.
pubmed: 29121268
Lin BD, Pinzón-Espinosa J, Blouzard E, Van Der Horst MZ, Okhuijsen-Pfeifer C, Van Eijk KR, et al. Associations between polygenic risk score loading, psychosis liability, and clozapine use among individuals with schizophrenia. JAMA Psychiatry. 2023;80:181–5.
pubmed: 36542388
doi: 10.1001/jamapsychiatry.2022.4234
WHO Collaborating Centre for Drug Statistics Methodology. Definition and general consideration 2023 [Available from: http://www.whocc.no/ddd/definition_and_general_considera/ .
FASS [Available from: https://www.fass.se/LIF/startpage?userType=0 .
Grunze H, Schlösser S, Amann B, Walden J. Anticonvulsant drugs in bipolar disorder. Dialog Clin Neurosci. 1999;1:24–40.
Kato T. Current understanding of bipolar disorder: toward integration of biological basis and treatment strategies. Psychiatry Clin Neurosci. 2019;73:526–40.
pubmed: 31021488
doi: 10.1111/pcn.12852
Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109–38.
pubmed: 20192788
doi: 10.1146/annurev.clinpsy.121208.131413
Vrieze SI. Model selection and psychological theory: a discussion of the differences between the Akaike information criterion (AIC) and the Bayesian information criterion (BIC). Psychol Methods. 2012;17:228–43.
pubmed: 22309957
pmcid: 3366160
doi: 10.1037/a0027127
Côté S, Tremblay RE, Nagin D, Zoccolillo M, Vitaro F. The development of impulsivity, fearfulness, and helpfulness during childhood: Patterns of consistency and change in the trajectories of boys and girls. J Child Psychol Psychiatry. 2002;43:609–18.
pubmed: 12120857
doi: 10.1111/1469-7610.00050
Rahman S, Wiberg M, Alexanderson K, Jokinen J, Tanskanen A, Mittendorfer-Rutz E. Trajectories of antidepressant medication use in individuals before and after being granted disability pension due to common mental disorders-a nationwide register-based study. BMC Psychiatry. 2018;18:1–10.
SAS Institute I. SAS/STAT® online documentation, version 9.4. Cary, N.C.: SAS Institute, Inc; 2012.
Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry. 2003;60:1187–92.
pubmed: 14662550
doi: 10.1001/archpsyc.60.12.1187
McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry. 2003;60:497–502.
pubmed: 12742871
doi: 10.1001/archpsyc.60.5.497
Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000;157:1552–62.
pubmed: 11007705
doi: 10.1176/appi.ajp.157.10.1552
Facal F, Costas J. Polygenic risk scores for schizophrenia and treatment resistance: new data, systematic review and meta-analysis. Schizophr Res. 2023;252:189–97.
pubmed: 36657363
doi: 10.1016/j.schres.2023.01.012
Lichtenstein P, Bjork C, Hultman CM, Scolnick E, Sklar P, Sullivan PF. Recurrence risks for schizophrenia in a Swedish national cohort. Psychol Med. 2006;36:1417–25.
pubmed: 16863597
doi: 10.1017/S0033291706008385
Sellgren C, Landen M, Lichtenstein P, Hultman CM, Langstrom N. Validity of bipolar disorder hospital discharge diagnoses: file review and multiple register linkage in Sweden. Acta Psychiatr Scand. 2011;124:447–53.
pubmed: 21838734
doi: 10.1111/j.1600-0447.2011.01747.x
Ekholm B, Ekholm A, Adolfsson R, Vares M, Osby U, Sedvall GC, et al. Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses. Nord J Psychiatry. 2005;59:457–64.
pubmed: 16316898
doi: 10.1080/08039480500360906
Kendler KS, Ohlsson H, Lichtenstein P, Sundquist J, Sundquist K. The genetic epidemiology of treated major depression in Sweden. Am J Psychiatry. 2018;175:1137–44.
pubmed: 30021458
doi: 10.1176/appi.ajp.2018.17111251
Sundquist J, Ohlsson H, Sundquist K, Kendler KS. Common adult psychiatric disorders in Swedish primary care (where most mental health patients are treated). BMC Psychiatry. 2017;17:235.
pubmed: 28666429
pmcid: 5493066
doi: 10.1186/s12888-017-1381-4
Bech P. Diagnostic and classification tradition of mental disorders in the 20th century in Scandinavia. In: Satorius N, editor. Sources and traditions of classification in psychiatry. Toronto: Hogrefe & Huber; 1990. p. 153–70.
Langfeldt G. Diagnosis and prognosis of schizophrenia. Proc R Soc Med. 1960;53:1047–52.
pubmed: 13758881
pmcid: 1871652
Fors BM, Isacson D, Bingefors K, Widerlöv B. Mortality among persons with schizophrenia in Sweden: an epidemiological study. Nord J Psychiatry. 2007;61:252–9.
pubmed: 17763118
doi: 10.1080/08039480701414932
Hujoel ML, Gazal S, Loh P-R, Patterson N, Price AL. Liability threshold modeling of case–control status and family history of disease increases association power. Nat Genet. 2020;52:541–7.
pubmed: 32313248
pmcid: 7210076
doi: 10.1038/s41588-020-0613-6
Krebs MB Appadurai V, Hellberg KLJ, Ohlsson H, Steinbach J, Pedersen EM, et al. The relationship between genotype- and phenotype-based estimates of genetic liability to human psychiatric disorders, in practice and in theory. medRxiv. 2023:epub.